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Abstract
Randomised controlled trials have shown that the policy of
mammographic screening confers a substantial and significant
reduction in breast cancer mortality. This has often been
accompanied, however, by an increase in breast cancer incidence,
particularly during the early years of a screening programme, which
has led to concerns about overdiagnosis, that is to say, the
diagnosis of disease that, if left undetected and therefore
untreated, would not become symptomatic. We used incidence
data from two randomised controlled trials of mammographic
screening, the Swedish Two-county Trial and the Gothenburg Trial,
to establish the timing and magnitude of any excess incidence of
invasive disease and ductal carcinoma in situ (DCIS) in the study
groups, to ascertain whether the excess incidence of DCIS
reported early in a screening trial is balanced by a later deficit in
invasive disease and provide explicit estimates of the rate of ‘real’
and non-progressive ‘overdiagnosed’ tumours from the study
groups of the trials. We used a multistate model for overdiagnosis
and used Markov Chain Monte Carlo methods to estimate the
parameters. After taking into account the effect of lead time, we
estimated that less than 5% of cases diagnosed at prevalence
screen and less than 1% of cases diagnosed at incidence screens
are being overdiagnosed. Overall, we estimate overdiagnosis to be
around 1% of all cases diagnosed in screened populations. These
estimates are, however, subject to considerable uncertainty. Our
results suggest that overdiagnosis in mammography screening is a
minor phenomenon, but further studies with very large numbers are
required for more precise estimation.
Introduction
Randomised controlled trials have shown that the policy of
mammographic screening confers a substantial and
significant reduction in breast cancer mortality [1-3]. There is
continuing interest in the human costs associated with the
mortality benefit, in particular, whether overdiagnosis occurs
in breast cancer screening and, if so, its magnitude [4,5]. In
this context, overdiagnosis means the diagnosis of cancer as
a result of screening, usually histologically confirmed, that
would not have arisen clinically during the lifetime of the host
had screening not taken place.
When a mammographic screening programme is initiated,
usually a large increase in breast cancer incidence is
observed in the early years of the programme, and a relatively
small increase later [4,6]. This in itself is not sufficient to imply
overdiagnosis, for the following reasons:
1.  In most parts of the world, breast cancer incidence was
increasing prior to the epoch of mammography. Thus at
least part of any excess incidence observed in the
screening epoch is probably due to an existing increasing
trend in incidence.
2.  In addition, the early diagnosis of cancers due to lead
time may exacerbate the underlying temporal increase by
bringing forward in time future higher rates of disease.
3. In relation to this, screening also causes an artificial
increase in age-specific incidence. With two years lead
time on average, we would observe age 52 incidence at
age 50, and so on.
4.  There will be a substantial excess in incidence in the first
few years of the programme due to the prevalence
screen: large numbers of asymptomatic tumours in the
prevalence pool will have their diagnosis date brought
forward to the time of the prevalence screen.
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5.  There will be a continuing excess thereafter at the lower
end of the age range for screening, due to prevalence
screens of subjects reaching the age for screening
eligibility.
That said, the increase could still be partly due to
overdiagnosis.
One would expect the excess incidence due to lead time to
be followed by a deficit in incidence in screened cohorts at
ages higher than the upper age limit for screening, as was
observed in the UK [6]. Estimation from the deficit, however,
is not straightforward, because usually one can identify
screened cohorts only at aggregate rather than individual
level, and it takes some years after screening before the
subsequent deficit becomes observable.
An issue of particular interest is overdiagnosis of ductal
carcinoma  in situ (DCIS) [7]. Here, the question of most
interest is: how much of the DCIS diagnosed at screening
would be expected to progress to invasive cancer if left
untreated? The DCIS that would have progressed represents
invasive cancers prevented, a major benefit of screening.
Those that would not have progressed represent
overdiagnosis and unnecessary treatment.
Essential to the concept and existence of overdiagnosis is the
duration of the preclinical screen-detectable period, the
sojourn time. Overdiagnosis can be thought of as a
combination of two disease entities. The first is the diagnosis
of a potentially progressive cancer in a subject who is going
to die of other causes in the near future in any case, possibly
from an accident, another occult disease or an unexpected
cerebrovascular or cardiovascular event, before the tumour
would have given rise to clinical symptoms. The second is an
extreme form of length bias whereby there are, in theory,
subclinical tumours with little or no potential to progress to
symptomatic disease, that is, whose sojourn time has a
radically different distribution from that of the general tumour
population.
The first of these must undoubtedly happen, but given the low
all-cause mortality rates of women in the age groups invited
for screening, and the likely mean and distribution of sojourn
time, this type of overdiagnosis is liable to be very rare [4]. It
would, therefore, seem more potentially productive in terms of
estimation to focus on the latter form of overdiagnosis, a
subpopulation of non-progressive or low-progression
tumours.
In this paper, we use two randomised controlled trials of
mammographic screening, the Swedish Two-county Trial and
the Gothenburg Trial, to address the following issues: the
timing and magnitude of excess incidence of invasive disease
and DCIS in the study groups compared to the control
groups; whether there is evidence that the excess incidence
of DCIS is balanced by a later deficit in invasive disease; and
explicit estimation of rates of ‘real’ tumours and non-
progressive ‘overdiagnosed’ tumours from the study groups
of the trials.
Methods
The design features of the two trials have been described in
detail elsewhere [1,8]. Briefly, in the Swedish Two-county
Trial, 77,080 women aged 40 to 74 years were randomised
to regular invitation to screening, and 55,985 to no invitation.
Screening was by single-view mammography, with an
interscreening interval of 2 years in women aged 40 to
49 years and 33 months in women aged 50 to 74 years at
randomisation. The trial began in late 1977. Around 7 years
later, after approximately 3 rounds of screening in the older
group and 4 rounds of screening in the younger, a mortality
reduction of 30% was observed and published [9], the
control group invited to screening and the screening phase of
the trial closed. Follow-up was continued for mortality from
the tumours diagnosed during the screening phase [1].
In the Gothenburg Trial, 21,650 women aged 39 to 59 years
were randomised to invitation to screening and 29,961 to no
invitation [8]. The screening was by two-view mammography
at first screen, with number of views thereafter dependent on
breast density. Screening took place at 18 month intervals.
The trial began in 1982. After five rounds of screening in the
1933 to 1944 birth cohorts (approximately the 39 to 49 year
age group at randomisation), the corresponding control
group members were offered screening and the screening
phase of the trial closed. In the 1923 to 1932 birth cohorts
(the 50 to 59 year age group), the control group was invited
to screening after four rounds. As in the Swedish Two-county
Trial, follow-up has continued for mortality from the tumours
diagnosed during the screening phase of the trial.
In both trials, the control group was offered screening at the
close of the screening phase, so we cannot estimate
overdiagnosis by a simple comparison of long term incidence
rates in the study and control groups. We can, however,
study the size and timing of excess incidence during the
screening phase to obtain clues to when overdiagnosis may
occur. Accordingly, our first analysis was to estimate
cumulative incidence rates of invasive, in situ and total
cancers in the study and control groups of each trial. It has
already been noted that in both trials incidence equalised
between study and control groups with the first screen of the
control group, suggesting that if there is overdiagnosis, it
occurs mainly at the first screen [2,8].
In the Gothenburg Trial, each individual year of birth cohort
(from 1923 to 1944) was randomised in succession, with a
study to control ratio chosen on the basis of the capacity of
the mammography facilities to screen the study group [8].
The variation of the randomisation ratio by year of birth
induced an age imbalance (albeit a very small imbalance)260
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between study and control groups. To take account of this,
the Gothenburg study group incidence is compared not with
the raw control group incidence but with the standardised
incidence that would have been observed in the control
group if it had had exactly the same year of birth distribution
as the study group [8].
Our second analysis involved explicit estimation of the
incidence of ‘real’ and ‘overdiagnosed’ cases from the
numbers of cases detected at screening and between
screens in the two trials. We assumed a uniform annual
incidence  I  of preclinical but screen detectable, truly
progressive cancers, an exponential distribution of time from
inception of these to clinical symptoms with rate λ, and a
screening test sensitivity S. In addition, we assume
exponential incidence of overdiagnosed (non-progressive)
preclinical screen-detectable cancers, with rate µ. Because a
tumour is only overdiagnosed if it is actually detected at
screening, we define the screening test sensitivity to be
100% for overdiagnosed cancers. In this model, there are
four states: no detectable disease, non-progressive
(overdiagnosed) preclinical disease, progressive preclinical
disease, and clinical symptomatic disease. The expected
rates of cancers diagnosed at first, second and third screens,
and in the intervals following those screens with an average
interval time of t are as follows.
First screen:
SI
+ (1 – e–µa)
λ
where a is average age (50 years in the Gothenburg Trial and
58 years in the Swedish Two-county Trial). The second
component in the expected rate represents the over-
diagnosed cancers.
This allows a constant incidence rate of non-progressive
disease from birth to age at first screen. This is arbitrary,
biologically unverifiable and it may be wrong. However, the
expected rates predicted for any multiplier of µ from 15 or 20
years upwards are very similar, and it seemed to us less
arbitrary to allow the subjects’ age to dictate our time limit
than to choose one ourselves, given the current low level of
knowledge of non-progressive disease.
Between first and second screen:
I
{– S(1 – e–λt) + λt}
λ




(1 – Se–λt) + (1 – e–µt)
λ
The second component in the expected rate represents the
overdiagnosed cancers.
Between second and third screen:
I
{(1 – S) (1 – Se–λt) (1 – e–λt) + λt – (1 – e–λt)}
λ




{(1 – S) (1 – Se–λt) e–λt + (1 – e–λt)} + (1 – e–µt)
λ
The second component in the expected rate represents the
overdiagnosed cancers.
Interval after third screen:
(1 – S)II (1 – e–λt)
{(1 – S) (1 – Se–λt) e–λt + (1 – e–λt)} + It – 
λλ
Since these are symptomatic tumours there is no term for
overdiagnosis.
From the data on screen-detected and interval cancers, we
estimated I, λ, S and µ by fitting Poisson distributions to the
numbers of cases at the three screens and in the three
intervals with expectations as above. For the Swedish Two-
county Trial, t = 2.56 years (the average interval for the
19,844 women younger than 50 years and the 57,236
women aged 50 to 74 years). For the Gothenburg Trial,
t = 1.5 years. The estimation algorithm used was Markov
Chain Monte Carlo (MCMC), implemented in the computer
programme WinBUGS [10]. The diagnostic criteria of
Geweke, Raftry and Lewis, and Heldelberger and Elch in
Convergence Diagnostics and Output Analysis Software
(CODA) were used to assess convergence of the MCMC
parameters [11]. The results for the chain provided no
evidence against convergence for all the parameters. We
intentionally chose uninformative prior distributions to
approximate a maximum likelihood solution. Results are
presented as mean posterior distribution values and 95%
credible intervals. The WinBUGS program updated a single
chain with 15,000 samples (with thinning of 1), from which
the first 5,000 samples were discarded (burn-ins) and the
remaining 10,000 samples were used in estimation. Prior
distributions used for the parameters I, λ, S and µ were as
follows: I, lognormal(0.0, 0.0001); λ, gamma(0.01, 0.01); S,
logit(S) = α, α ~ normal(0.0, 0.0001); µ, lognormal(0.0, 0.01).
Note that the second parameter in the normal and lognormal
distributions is the precision, and not the variance or the
standard deviation [10].
Results
Figure 1a-c shows the cumulative incidence of invasive
breast cancer, DCIS, and all breast cancers in the study and261
control groups of the Swedish Two-county Trial. Figure 2a-c
shows the corresponding absolute excesses/deficits in the
study group over time, per thousand women randomised. As
noted above, the overall rates equalised at years 8 to 9, once
the first screen of the control group was complete. The study
group excess in DCIS rates peaked at 6 to 7 years and was
balanced by a deficit in invasive tumours at 8 to 9 years, with
the screening of the control group. The absolute excess of
DCIS cases in the study group was 60 tumours, and the
deficit of invasive tumours was 68, suggesting no over-
diagnosis at all. If, conservatively, we exclude DCIS cases
diagnosed at the first screen of the control group, there was
an excess of 86 DCIS cases in the study group, suggesting a
total overdiagnosis of 18 DCIS cases. This amounts to 15%
of all DCIS cases and 1% of all tumours. This can be
regarded as an upper limit on the amount of overdiagnosis of
DCIS in the trial.
Figure 3a-c shows the corresponding cumulative incidences
in the Gothenburg Trial.
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Figure 1
Cumulative incidence of breast cancers in study and control groups of
the Swedish Two-county Trial. (a) Invasive cancers. (b) In situ cancers.
(c) All cancers.
Figure 2
Cumulative excess incidence (study versus control) of breast cancers
in the Swedish Two-county Trial. (a) Invasive cancers. (b) In situ
cancers. (c) All cancers.262
There was a substantial proportional excess, but very small
absolute excess of in situ cancers, which was again balanced
by a deficit in invasive cancers (Fig. 4). The excess of in situ
cancers peaked at 4 to 5 years. Overall rates equalised at 6
to 7 years, around the time of screening the control group.
The absolute excess of DCIS cases was 10, and the deficit of
invasive cases was 28, again suggesting no overdiagnosis of
DCIS. After exclusion of DCIS cases diagnosed at the first
screen of the control group, the excess in the study group
was 35, and the overall balance of all tumour types therefore
suggested 7 overdiagnosed cases, 18% of DCIS and 2% of
all study group cancers, a likely upper limit on overdiagnosis
of DCIS in this study.
Table 1 shows the numbers screened and cancers detected
at the first three screens and in the interval after each of the
first three screens in the study group of the Swedish Two-
county Trial. Applying the overdiagnosis model to these data
gives the results in Table 2. These results pertain to all
Breast Cancer Research    December 2005 Vol 7 No 6 Duffy et al.
Figure 3
Cumulative incidence of breast cancers in study and control groups of
the Gothenburg Trial. (a) Invasive cancers. (b) In situ cancers. (c) All
cancers.
Figure 4
Cumulative excess incidence (study versus control) of breast cancers
in the Gothenburg Trial. (a) Invasive cancers. (b) In situ cancers. (c)
All cancers.263
cancers, invasive and in situ, but it should be noted that very
similar results were obtained using invasive cancers only.
Results indicate percentages of tumours overdiagnosed of
3.1%, 0.3% and 0.3% at the first, second and third screens,
respectively. This implies a total of 14 tumours over-
diagnosed, 1% of all tumours, screen-detected and clinical,
arising during the period of observation. We also re-
estimated the parameters restricting the data to the 40 to
69 year age group, as the 70 to 74 year age group was only
invited to the first two screens. Results were very similar,
giving overdiagnosis rates of 3%, 0.2% and 0.2% at the first
three screens, and an overall percentage overdiagnosed of
1% of all tumours diagnosed in the programme.
Table 3 shows the corresponding data for the Gothenburg
Trial, and Table 4 the results of overdiagnosis modelling from
the Gothenburg data. Results show 4.2% overdiagnosis at
first screen and 0.3% at subsequent screens. This corres-
ponds to three cancers diagnosed, two percent of all tumours
diagnosed in the first three screening rounds. Restriction of
the analysis to invasive tumours only reduces the
overdiagnosis estimates by around one-third.
Discussion
We have derived formal estimates of overdiagnosis from
empirical breast screening data. The estimates take into
account the effect of lead time and use direct estimation of
the underlying incidence of both ‘true’ and ‘overdiagnosed’
cases from the screened populations. We found over-
diagnosis to be a minor phenomenon, with less than 5% of
cases diagnosed at prevalence screen and less than 1% of
cases at incidence screens being overdiagnosed. Over-
diagnosis was estimated at around 1% of all cases
diagnosed in the screened populations.
Examination of absolute incidence rates of DCIS and invasive
disease suggest further that overdiagnosis of DCIS is not the
major problem it is claimed to be [12]. While large relative
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Table 1
Cancers diagnosed at and after the first three screens,
Swedish Two-County Trial
Number Invasive 
Detection occasion screened cancers only All cancers
First screen 68,770 384 426
First interval 68,770 123 134
Second screen 58,601 214 244
Second interval 58,601 78 82
Third screen 43,320 173 193
Third interval 43,320 89 91
Table 2
Estimates from formal overdiagnosis modelling, Swedish Two-
county Trial data, ages 40 to 74 years
Quantity Estimate 95% CI
Incidence (true cases)/1000 (I) 2.2 (2.0-2.4)
Screening test sensitivity (S) as % 99.9 (99.6-100)
Progression to clinical cancer (λ) 0.34 (0.31-0.38)
Incidence of overdiagnosed cases/1000 (µ) 0.0038 (0.0001-0.0011)
Percent overdiagnosis (first screen) 3.1 (0.1-10.9)
Percent overdiagnosis (second screen) 0.3 (0.1-1.0)
Percent overdiagnosis (third screen) 0.3 (0.1-1.0)
CI, confidence interval.
Table 3
Cancers diagnosed at and after the first three screens,
Gothenburg Trial
Number Invasive 
Detection occasion screened cancers only All cancers
First screen 18,197 55 70
First interval 18,197 7 9
Second screen 17,005 27 28
Second interval 17,005 14 14
Third screen 17,093 36 41
Third interval 17,093 21 23
Table 4
Estimates from formal overdiagnosis modelling, Gothenburg
Trial data, ages 39 to 59 years
Quantity Estimate 95% CI
Incidence (true cases)/1000 (I) 1.9 (1.6-2.3)
Screening test sensitivity (S) 99.9 (99.6-100)
Progression to clinical cancer (λ) 0.52 (0.41-0.67)
Incidence of overdiagnosed cases/1000 (µ) 0.0034 (0.0000-0.0238)
Percent overdiagnosis (first screen) 4.2 (0.0-28.8)
Percent overdiagnosis (second screen) 0.3 (0.0-2.0)
Percent overdiagnosis (third screen) 0.3 (0.0-2.0)
CI, confidence interval.264
increases in DCIS rates have been cited as evidence for such
overdiagnosis [12], absolute rates of detection of DCIS
remain low, at around one per thousand screened [13].
Previous detailed estimation of DCIS progression is in agree-
ment with our results [14].
Other estimates of overdiagnosis in the literature range from
5% or less [4] up to 30% [15]. The latter, however, does not
formally take into account the lead time effect, and does not
fully identify screened and unscreened cohorts. We would
suggest that simple estimation of rates at an aggregate level,
while useful, is not sufficient in itself to derive conclusive
estimates of overdiagnosis rates.
Our estimates of incidence of preclinical disease in the two
trials are similar to the clinical incidence rates in the
respective control groups before their exit screen (2.1 per
1,000 and 1.8 per 1,000 for the Swedish Two-county and
Gothenburg Trials, respectively). It should be noted that we
have wide confidence intervals on our overdiagnosis
estimates, and the estimate of screening test sensitivity tends
to drift to its boundary at 100%. Also, there is some
sensitivity to the prior distribution for µ, the incidence rate of
overdiagnosed cancers, uniform priors tending to give higher
estimates of µ. For more stable estimation, perhaps overview
estimates from several screening programmes, as in Yen et
al. [14], are indicated.
In both trials, our estimate of sensitivity drifted towards its
upper bound of 100%. Two points should be noted here.
Firstly, the part of the likelihood related to the prevalence
screen is monotonic increasing in S, as are the parts related
to incidence screens under most circumstances. The
likelihood component related to the interval cancers is not,
but if there are very few interval cancers, this can be
outweighed by the likelihood pertaining to screen-detected
cancers. This reflects the fact that a very high sensitivity is
implied if there are very low interval cancer rates. Secondly,
our sensitivity estimate is of test sensitivity, not program
sensitivity, which includes all interval cancers as false
negatives. Our estimate differs from that of others [16],
largely because it takes account of the sojourn time in
estimation of the proportion of interval cancers that are really
newly arising since the screen, as opposed to those missed
at the screen. As noted above, if the observed number of
interval cancers is small, the estimate of S must be close to
100%. It should be noted that the maximum likelihood
estimate of S would also be 100%.
The models we have fitted here are rather simple. Only a single
overdiagnosis parameter is estimated. There is room for
improvement, in terms of estimation of age-specific over-
diagnosis rates, for example. Multiple overdiagnosis parameters,
and the small numbers resulting when analysis is restricted to
age subgroups, both give rise to instability of estimation. Solving
this problem is a target of ongoing research.
It would be of some interest to see estimates from formal
models from other screening trials and service screening
programmes. In the meantime, the results here suggest that
overdiagnosis in mammography screening is a minor
phenomenon. We need more data to reduce the uncertainty
around these estimates.
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